AZ/Amgen Fail In EU Fast-Track Bid For Tezepelumab

Asthma Drug Marketing Application Will Be Reviewed Under Standard Timelines

 
• By Maureen Kenny

European drug reviewers are not convinced that AstraZeneca and Amgen's investigational treatment for severe asthma, tezepelumab, should be fast-tracked through the EU evaluation system once the companies file for approval.

Shortness of breath
People with severe asthma are increasingly being treated with biologic therapies • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards